Labcorp (NYSE: LH) EVP Caveney details RSU vesting and tax withholdings

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, reported multiple equity transactions tied to vested restricted stock units. On February 6 and 7, 2026, a total of 670, 517 and 111 restricted stock units converted into the same number of Labcorp common shares at an exercise price of $0 per share. Shares were then withheld on February 6 and 9, 2026 to cover tax obligations, including 209 shares at $277.2 per share and 148 and 32 shares at $274.01 per share. After these transactions, Caveney directly owned 31,077.9234 Labcorp common shares, and 2,890 restricted stock units remained outstanding.

Insider Trade Summary

1,298 shares exercised/converted

Mixed 9 txns

Insider Caveney Brian J

Role EVP, Pres of ED, CMO & CSO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	148	$274.01	$41K
Tax Withholding	Common Stock	32	$274.01	$9K
Exercise	Restricted Stock Unit	517	$0.00	--
Exercise	Restricted Stock Unit	111	$0.00	--
Exercise	Common Stock	517	$0.00	--
Exercise	Common Stock	111	$0.00	--
Exercise	Restricted Stock Unit	670	$0.00	--
Exercise	Common Stock	670	$0.00	--
Tax Withholding	Common Stock	209	$277.20	$58K

Holdings After Transaction: Common Stock — 31,109.923 shares (Direct); Restricted Stock Unit — 3,001 shares (Direct)

Footnotes (1)

Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Amount includes 57.1306 shares acquired on June 30, 2025 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan and 45.1355 shares acquired on December 31, 2025 under the Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan. Stock withholding to satisfy tax withholding obligations. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. This number reflects the aggregate number of Restricted Stock Units held by the reporting person. The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested.

Form 4 Insider Transactions: What Each Field Means →

02/10/2026 - 03:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caveney Brian J

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Pres of ED, CMO & CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2026		M		670	A	⁽¹⁾	30,838.9234⁽²⁾	D
Common Stock	02/06/2026		F⁽³⁾		209	D	$277.2	30,629.9234	D
Common Stock	02/07/2026		M		517	A	⁽¹⁾	31,146.9234	D
Common Stock	02/07/2026		M		111	A	⁽¹⁾	31,257.9234	D
Common Stock	02/09/2026		F⁽³⁾		148	D	$274.01	31,109.9234	D
Common Stock	02/09/2026		F⁽³⁾		32	D	$274.01	31,077.9234	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	02/06/2026		M			670	⁽⁴⁾	⁽⁴⁾	Common Stock	670	$0	3,518⁽⁵⁾	D
Restricted Stock Unit	⁽¹⁾	02/07/2026		M			517	⁽⁶⁾	⁽⁶⁾	Common Stock	517	$0	3,001⁽⁵⁾	D
Restricted Stock Unit	⁽¹⁾	02/07/2026		M			111	⁽⁶⁾	⁽⁶⁾	Common Stock	111	$0	2,890⁽⁵⁾	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. Amount includes 57.1306 shares acquired on June 30, 2025 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan and 45.1355 shares acquired on December 31, 2025 under the Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan.

3. Stock withholding to satisfy tax withholding obligations.

4. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

6. The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Brian J. Caveney	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Labcorp (LH) executive Brian Caveney report in this Form 4?

Brian J. Caveney reported restricted stock units converting into Labcorp common stock and related tax withholding share transactions. Multiple RSU tranches vested at a $0 exercise price, and some of the resulting shares were withheld to satisfy tax obligations at prices above $270 per share.

How many Labcorp (LH) shares does Brian Caveney own after these transactions?

After the reported transactions, Brian J. Caveney directly owned 31,077.9234 shares of Labcorp common stock. This figure reflects the net result of RSU conversions to shares and shares withheld to cover tax obligations on February 6 and 9, 2026.

What is the role of Brian Caveney at Labcorp (LH) in this filing?

Brian J. Caveney is identified as an officer of Labcorp, serving as EVP, President of Enterprise Diagnostics, Chief Medical Officer and Chief Scientific Officer. The Form 4 details changes in his beneficial ownership of Labcorp common stock and restricted stock units.

What do the transaction codes M and F mean in the Labcorp (LH) Form 4?

Code M indicates the exercise or conversion of derivative securities, here restricted stock units turning into an equal number of Labcorp shares at $0. Code F represents shares withheld by the company to satisfy income tax withholding obligations associated with those equity awards.

How many restricted stock units does Brian Caveney still hold in Labcorp (LH)?

Following the reported conversions, Brian J. Caveney held 2,890 restricted stock units. Footnotes explain these units represent contingent rights to receive an equal number of Labcorp common shares and that certain RSU grants vest in three equal annual installments.

At what prices were Labcorp (LH) shares withheld for Brian Caveney’s taxes?

Labcorp withheld 209 shares at $277.2 per share on February 6, 2026, and 148 and 32 shares at $274.01 per share on February 9, 2026. These withholdings were specifically described as stock withholding to satisfy tax obligations.